CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib.
作者信息
Vos Josephine M, Tsakmaklis Nickolas, Patterson Christopher J, Meid Kirsten, Castillo Jorge J, Brodsky Philip, Ganz Tomas, Pals Steven T, Kersten Marie José, Xu Lian, Yang Guang, Treon Steven P, Hunter Zachary R
机构信息
St. Antonius Hospital, Nieuwegein, The Netherlands
Bing Center for WM, Dana Farber Cancer Insitute, Boston, MA, USA.
出版信息
Haematologica. 2017 Nov;102(11):e452-e455. doi: 10.3324/haematol.2017.172627. Epub 2017 Aug 10.
Abstract
摘要
相似文献
1
CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib.
Haematologica. 2017 Nov;102(11):e452-e455. doi: 10.3324/haematol.2017.172627. Epub 2017 Aug 10.
2
Efficacy of ibrutinib in the treatment of Bing-Neel syndrome.
Am J Hematol. 2016 Mar;91(3):E17-9. doi: 10.1002/ajh.24279.
3
Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound.
Am J Hematol. 2018 Aug;93(4):511-517. doi: 10.1002/ajh.25023. Epub 2018 Jan 25.
4
Resolution of Waldenström Macroglobulinemia-Associated Autoimmune Hemolysis With Ibrutinib.
J Oncol Pract. 2016 May;12(5):490-1. doi: 10.1200/JOP.2016.011932.
5
Ibrutinib in the management of Waldenstrom macroglobulinemia.
J Oncol Pharm Pract. 2019 Mar;25(2):434-441. doi: 10.1177/1078155218786037. Epub 2018 Jul 12.
6
Ibrutinib in previously treated Waldenström's macroglobulinemia.
N Engl J Med. 2015 Apr 9;372(15):1430-40. doi: 10.1056/NEJMoa1501548.
7
Ibrutinib for the treatment of Waldenström macroglobulinemia.
Expert Rev Hematol. 2015 Oct;8(5):569-79. doi: 10.1586/17474086.2015.1061427. Epub 2015 Jul 2.
8
First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
Hematol Oncol Clin North Am. 2018 Oct;32(5):853-864. doi: 10.1016/j.hoc.2018.05.012. Epub 2018 Jul 19.
9
ibrutinib (IMBRUVICA°) and Waldenström's macroglobulinaemia.
Prescrire Int. 2016 Oct;25(175):232.
10
Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia.
Haematologica. 2018 Jul;103(7):e307-e310. doi: 10.3324/haematol.2017.186908. Epub 2018 Feb 22.
引用本文的文献
1
A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings.
Front Immunol. 2025 Jan 21;15:1369619. doi: 10.3389/fimmu.2024.1369619. eCollection 2024.
2
Serum CXCL13 level is related to treatment response and predicts disease prognosis in Waldenström macroglobulinemia.
Ann Hematol. 2024 Sep;103(9):3667-3675. doi: 10.1007/s00277-024-05690-3. Epub 2024 Mar 6.
3
CXC chemokine ligand 13 and galectin-9 plasma levels collaboratively provide prediction of disease activity and progression-free survival in chronic lymphocytic leukemia.
Ann Hematol. 2024 Mar;103(3):781-792. doi: 10.1007/s00277-023-05540-8. Epub 2023 Nov 9.
4
CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression.
J Hematol Oncol. 2022 Oct 10;15(1):144. doi: 10.1186/s13045-022-01366-5.
5
Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy.
Blood Adv. 2022 Feb 8;6(3):1015-1024. doi: 10.1182/bloodadvances.2021006106.
6
Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review.
Metabol Open. 2021 Sep;11:100116. doi: 10.1016/j.metop.2021.100116. Epub 2021 Jul 29.
7
Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.
Blood. 2021 Sep 30;138(13):1099-1109. doi: 10.1182/blood.2020006783.
8
Defining an Ultra-Low Risk Group in Asymptomatic IgM Monoclonal Gammopathy.
Cancers (Basel). 2021 Apr 23;13(9):2055. doi: 10.3390/cancers13092055.
9
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia.
J Clin Oncol. 2021 Feb 20;39(6):565-575. doi: 10.1200/JCO.20.00555. Epub 2020 Sep 15.
10
Immunopathology of Hyperinflammation in COVID-19.
Am J Pathol. 2021 Jan;191(1):4-17. doi: 10.1016/j.ajpath.2020.08.009. Epub 2020 Sep 11.
本文引用的文献
1
Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.
Blood. 2016 Aug 11;128(6):827-38. doi: 10.1182/blood-2016-03-708263. Epub 2016 Jun 14.
2
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
Clin Cancer Res. 2016 Apr 1;22(7):1572-82. doi: 10.1158/1078-0432.CCR-15-1965. Epub 2015 Dec 9.
3
Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.
Br J Haematol. 2016 Mar;172(5):735-44. doi: 10.1111/bjh.13897. Epub 2015 Dec 13.
4
Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia.
Haematologica. 2016 Mar;101(3):e111-5. doi: 10.3324/haematol.2015.137265. Epub 2015 Dec 3.
5
MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia.
N Engl J Med. 2015 Aug 6;373(6):584-6. doi: 10.1056/NEJMc1506192.
6
Ibrutinib in previously treated Waldenström's macroglobulinemia.
N Engl J Med. 2015 Apr 9;372(15):1430-40. doi: 10.1056/NEJMoa1501548.
7
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.
Blood. 2013 Aug 15;122(7):1222-32. doi: 10.1182/blood-2012-12-475111. Epub 2013 Jul 8.
8
Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.
Br J Haematol. 2013 Jan;160(2):171-6. doi: 10.1111/bjh.12102. Epub 2012 Nov 15.
9
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
N Engl J Med. 2012 Aug 30;367(9):826-33. doi: 10.1056/NEJMoa1200710.
10
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
Blood. 2012 Mar 15;119(11):2590-4. doi: 10.1182/blood-2011-11-390989. Epub 2012 Jan 25.
Zotero 插件